Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sky Pharma Co., Ltd.
Sendai, Miyagi, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
Sky Pharma is developing low molecular weight compounds for regenerative medicine targeting nervous system disorders including glaucoma and spinal cord injury, with ongoing joint research and patent filings but no reported clinical trials.[1][3]
- Therapeutic areas
- NeurologyOphthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Regenesome Co., Ltd.Tohoku University Graduate School of Dentistry
Beyond the preview
Go deeper on Sky Pharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sky Pharma Co., Ltd..